AU2019245403B2 - Imidazopiperazine inhibitors of transcription activating proteins - Google Patents

Imidazopiperazine inhibitors of transcription activating proteins Download PDF

Info

Publication number
AU2019245403B2
AU2019245403B2 AU2019245403A AU2019245403A AU2019245403B2 AU 2019245403 B2 AU2019245403 B2 AU 2019245403B2 AU 2019245403 A AU2019245403 A AU 2019245403A AU 2019245403 A AU2019245403 A AU 2019245403A AU 2019245403 B2 AU2019245403 B2 AU 2019245403B2
Authority
AU
Australia
Prior art keywords
mmol
compound
methyl
mixture
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019245403A
Other languages
English (en)
Other versions
AU2019245403A1 (en
Inventor
Christopher L. Carroll
Jason Cross
Philip Jones
Kang Le
Pijus K. Mandal
Timothy J. MCAFOOS
Michael J. Soth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2019245403A1 publication Critical patent/AU2019245403A1/en
Application granted granted Critical
Publication of AU2019245403B2 publication Critical patent/AU2019245403B2/en
Priority to AU2025202971A priority Critical patent/AU2025202971A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019245403A 2018-03-29 2019-03-29 Imidazopiperazine inhibitors of transcription activating proteins Active AU2019245403B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202971A AU2025202971A1 (en) 2018-03-29 2025-04-29 Imidazopiperazine inhibitors of transcription activating proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650151P 2018-03-29 2018-03-29
US62/650,151 2018-03-29
PCT/US2019/024976 WO2019191667A1 (en) 2018-03-29 2019-03-29 Imidazopiperazine inhibitors of transcription activating proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202971A Division AU2025202971A1 (en) 2018-03-29 2025-04-29 Imidazopiperazine inhibitors of transcription activating proteins

Publications (2)

Publication Number Publication Date
AU2019245403A1 AU2019245403A1 (en) 2020-10-22
AU2019245403B2 true AU2019245403B2 (en) 2025-02-06

Family

ID=68057632

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019245403A Active AU2019245403B2 (en) 2018-03-29 2019-03-29 Imidazopiperazine inhibitors of transcription activating proteins
AU2025202971A Pending AU2025202971A1 (en) 2018-03-29 2025-04-29 Imidazopiperazine inhibitors of transcription activating proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202971A Pending AU2025202971A1 (en) 2018-03-29 2025-04-29 Imidazopiperazine inhibitors of transcription activating proteins

Country Status (12)

Country Link
US (3) US11058688B2 (https=)
EP (1) EP3773587A4 (https=)
JP (1) JP7387627B2 (https=)
KR (1) KR102815607B1 (https=)
CN (1) CN112165944B (https=)
AU (2) AU2019245403B2 (https=)
BR (1) BR112020019824A2 (https=)
CA (1) CA3095367A1 (https=)
IL (1) IL277628A (https=)
RU (1) RU2020131507A (https=)
WO (1) WO2019191667A1 (https=)
ZA (1) ZA202006092B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019245403B2 (en) 2018-03-29 2025-02-06 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
AU2021259814B2 (en) * 2020-04-25 2023-09-28 Pharmablock Sciences (Nanjing), Inc. CBP/EP300 inhibitor and use thereof
JP7777131B2 (ja) * 2020-10-02 2025-11-27 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
WO2022072648A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
KR102910851B1 (ko) * 2021-04-21 2026-01-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도
CN113429427A (zh) * 2021-07-05 2021-09-24 湖南南新制药股份有限公司 杂环化合物及其制备方法和药物用途
CN115724857B (zh) * 2021-08-25 2024-06-21 杭州禹泓医药科技有限公司 一种芳杂环类化合物、含其的药物组合物及其应用
CN116410211A (zh) * 2021-12-29 2023-07-11 山东新时代药业有限公司 一种苯并呋喃类化合物
TW202340164A (zh) * 2022-01-21 2023-10-16 大陸商深圳默元生物科技有限公司 Ｎ－羥基喹啉甲醯胺化合物及其用途
WO2023235809A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Cgas inhibitors
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086200A9 (en) * 2014-11-27 2016-06-23 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2017205538A1 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537114B8 (en) 2002-08-07 2007-10-03 Novartis AG Organic compounds as agents for the treatment of aldosterone mediated conditions
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
MX2008015008A (es) 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
ATE545647T1 (de) 2006-12-22 2012-03-15 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
EA021293B1 (ru) * 2008-12-08 2015-05-29 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2528918B1 (en) 2010-01-29 2014-09-10 Nerviano Medical Sciences S.r.l. 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
CN103087067A (zh) * 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途
EP2920173B1 (en) 2012-10-18 2016-11-23 Bristol-Myers Squibb Company Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
JP2016525503A (ja) * 2013-06-28 2016-08-25 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
WO2016055028A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Therapeutic compounds and uses thereof
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
AU2019245403B2 (en) 2018-03-29 2025-02-06 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086200A9 (en) * 2014-11-27 2016-06-23 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2017205538A1 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer

Also Published As

Publication number Publication date
BR112020019824A2 (pt) 2021-01-05
EP3773587A4 (en) 2021-09-29
KR20210003764A (ko) 2021-01-12
JP7387627B2 (ja) 2023-11-28
US20190298729A1 (en) 2019-10-03
CN112165944A (zh) 2021-01-01
US20230008047A1 (en) 2023-01-12
RU2020131507A (ru) 2022-05-04
CN112165944B (zh) 2024-04-09
AU2019245403A1 (en) 2020-10-22
ZA202006092B (en) 2022-11-30
US20250127792A1 (en) 2025-04-24
US11058688B2 (en) 2021-07-13
CA3095367A1 (en) 2019-10-03
AU2025202971A1 (en) 2025-05-15
US12186324B2 (en) 2025-01-07
JP2021519308A (ja) 2021-08-10
IL277628A (en) 2020-11-30
KR102815607B1 (ko) 2025-05-30
EP3773587A1 (en) 2021-02-17
WO2019191667A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
AU2019245403B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US11434233B2 (en) Heterocyclic inhibitors of ATR kinase
US10899769B2 (en) Imidazopiperazinone inhibitors of transcription activating proteins
CA3024706A1 (en) Heterocyclic inhibitors of ptpn11
WO2019036641A1 (en) HETEROCYCLIC INHIBITORS OF KINASE ATR
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
US20160002248A1 (en) Gls1 inhibitors for treating disease
US12540139B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
HK40028148A (en) Heterocyclic inhibitors of atr kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)